Fu Rui Group develops Fu Rui shares.

After ten years' efforts, Inner Mongolia Furuimeng Chinese Medicine Technology Co., Ltd. has now become a modern pharmaceutical enterprise integrating scientific research, production, sales and network services. Since 1999 went on the market, the main product, Compound Biejia Ruangan Tablet, has occupied the first position in the field of liver fibrosis treatment. The company's business performance is outstanding, and it has been continuously rated as an advanced enterprise and advanced taxpayer by the local government, and a taxpayer with tax credit.

The leading product of Inner Mongolia Furuimeng Traditional Chinese Medicine Technology Co., Ltd., Compound Biejia Ruangan Tablet, 1999 won the third prize of national scientific and technological progress, and 200 1 was recognized as a high-tech achievement by the Science and Technology Department of Inner Mongolia Autonomous Region. In 2003, it was approved by the US Food and Drug Administration as a protected variety of traditional Chinese medicine, and was awarded an invention patent by the State Patent Office. On June 5438+ 10, 2000, the company took the lead in passing the GMP certification organized by the State Food and Drug Administration of the United States, and became the first pharmaceutical manufacturer in the autonomous region to pass the GMP certification. In 2002, it was recognized as a high-tech enterprise by the Ministry of Science and Technology, and in 2008, it was jointly awarded the qualification certification of autonomous region-level technology center by the Economic Commission of Inner Mongolia Autonomous Region and the Science and Technology Department. The company now has more than 200 sets of large and medium-sized production equipment, which can simultaneously produce more than 50 kinds of drugs in three categories: tablets, capsules and rubber ointments, reaching the advanced level of the pharmaceutical industry. Through the cooperation with large scientific research institutions, universities and well-known enterprises at home and abroad, we have formed a powerful, efficient and pragmatic R&D system, made breakthroughs in the field of liver disease diagnosis and treatment, and formed a unique core competitiveness.